FLT3
Cluster of differentiation antigen 135; CD135; Fms like tyrosine kinase 3
FLT3 (Fms-like tyrosine kinase 3, CD135) is a protein that in humans is encoded by the FLT3 gene. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. FLT3 is the receptor for the cytokine Flt3 ligand (FLT3L). FLT-3 is expressed on the surface of many hematopoietic progenitor cells. Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. The FLT3 gene is one of the most frequently mutated genes in acute myeloid leukemia (AML). Besides, high levels of wild-type FLT3 have been reported for blast cells of some AML patients without FLT3 mutations. These high levels may be associated with worse prognosis. Signaling through FLT3 plays a role in cell survival, proliferation, and differentiation. FLT3 is important for lymphocyte (B cell and T cell) development, but not for the development of other blood cells. Two cytokines that down modulate FLT3 activity are TNF-Alpha and TGF-Beta.
All Product Categories
-
FLT3 Inhibitors
(308)
View all products
-
FLT3 Antagonist
(1)
View all products
-
FLT3 Modulator
(1)
View all products
-
FLT3 Degraders
(12)
View all products
-
FLT3 Control
(1)
View all products
-
FLT3 Substrate
(1)
View all products
-
FLT3 Ligands
(6)
View all products
-
Flt-3/CD135 Proteins
(11)
View all products
-
FLT3 Related Products (336)
Related Products (336)
-
Recombinant Proteins (11)
-
FLT3-IN-14
0 ImagesCat. No.: HY-144777CAS No.: 2620551-45-1
-
FLT3-IN-25
0 ImagesCat. No.: HY-162032FLT3-IN-25 (compound 17) is a potent inhibitor of FLT3, with IC50s of 1.2 nM, 1.4 nM and 1.1 nM for FLT3-WT, FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-25 plays an important role in acute myeloid leukemia (AML).
-
FLT3-IN-43
0 ImagesCat. No.: HY-189246FLT3-IN-43 is an orally active inhibitor of tubulin and FLT3 kinase, with an IC50 of 3.6 μM against tubulin and an IC50 of 58.6 nM against human FLT3 kinase. FLT3-IN-43 binds to the colchicine-binding site on tubulin to inhibit microtubule polymerization. FLT3-IN-43 suppresses FLT3 kinase activity. FLT3-IN-43 disrupts the cellular microtubule network. Tubulin-IN-69 induces cell cycle arrest. Tubulin-IN-69 induces tumor cell apoptosis. FLT3-IN-43 is used for research on acute myeloid leukemia and solid tumors including colorectal cancer, lung adenocarcinoma, and breast cancer.
-
CHEMBL4444839
0 ImagesCat. No.: HY-173363CAS No.: 2316841-82-2CHEMBL4444839 is an inhibitor of FLT3 and can be used in the research of acute myeloid leukemia (AML).
-
FLT3/HDAC-IN-2
0 ImagesCat. No.: HY-162906FLT3/HDAC-IN-2 is (compound 25h) a FLT3/HDAC dual inhibitor. FLT3/HDAC-IN-2 has antiproliferative activity against MOLM-13 cells. FLT3/HDAC-IN-2 can be used in acute myeloid leukemia research.
-
VEGFR2-IN-84
0 ImagesCat. No.: HY-182354CAS No.: 861877-12-5VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold. VEGFR2-IN-84 inhibits VEGFR2 with sub-nanomolar affinity and broadly targets kinases including Kit, FGFR, PDGFR, and Ret. By competitively binding to the ATP-binding pocket, VEGFR2-IN-84 blocks the phosphorylation of VEGFR2 and its downstream AKT/ERK signaling pathway, thereby significantly inhibiting endothelial cell proliferation, migration, and tumor angiogenesis. VEGFR2-IN-84 exhibits broad-spectrum antiproliferative activity against various solid tumors such as liver cancer, lung cancer, and renal cancer, shows weak toxicity to normal cells, and has superior potency to Lenvatinib (HY-10981). VEGFR2-IN-84 possesses favorable pharmacokinetic properties and high safety (LD50>2000 mg/kg), and can be used in related studies of various malignant tumors.
-
FLT3 Ligand-Linker Conjugate 1
0 ImagesCat. No.: HY-170769CAS No.: 2769753-49-1FLT3 Ligand-Linker Conjugate 1 (compound 7) contains the FLT3 ligand and a PROTAC linker, which can recruit the E3 ligase VHL. FLT3 Ligand-Linker Conjugate 1 can be used to synthesize the PROTAC RSS0680 (HY-148062). PROTAC RSS0680 is a bifunctional compound that targets protein degradation of kinases.
-
PDGFRα/FLT3-ITD-IN-1
0 ImagesCat. No.: HY-145902CAS No.: 2761259-05-4PDGFRα/FLT3-ITD-IN-1 (Compound 12d) is a potent inhibitor of PDGFRα/FLT3 with IC50s of more than 0.036 and 0.003 μM, respectively. PDGFRα/FLT3-ITD-IN-1 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia.
-
FLT3-IN-16-d1
0 ImagesCat. No.: HY-148036SFLT3-IN-16-d1 is the deuterium labeled FLT3-IN-16 (HY-148036). FLT3-IN-16 is a potent FLT3 inhibitor with an IC50 of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia.
-
FLT3/VEGFR2-IN-1
0 ImagesCat. No.: HY-168493FLT3/VEGFR2-IN-1 (Compound 26) is a FLT3/VEGFR2/HDAC inhibitor with IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM for FLT3, VEGFR2, and HDAC1, respectively. FLT3/VEGFR2-IN-1 can inhibit the phosphorylation of STAT3 and ERK1/2 and the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 has anti-tumor activity and can be used for the research of acute myeloid leukemia.
-
FLT3-IN-18
0 ImagesCat. No.: HY-148522CAS No.: 752191-77-8FLT3-IN-18 is a potent and selective FLT3 inhibitor with an IC50 value of 0.003 μM. FLT3-IN-18 induces apoptosis and cell cycle arrest at G1 phase. FLT3-IN-18 inhibits FLT3 and STAT5 phosphorylation. FLT3-IN-18 has the potential for the research of acute myeloid leukemia (AML).
-
(R)-3-Hydroxy Midostaurin
0 ImagesCat. No.: HY-108263BCAS No.: 155848-20-7Synonyms: (R)-CGP52421(R)-3-Hydroxy Midostaurin ((R)-CGP52421) is a potent kinases inhibitor. (R)-3-Hydroxy Midostaurin is a major metabolite of midostaurin (PKC412; HY-10230) undergoing by the hepatic CYP3A4 enzyme. (R)-3-Hydroxy Midostaurin has the potential for acute myeloid leukemia (AML).
-
LS-104
0 ImagesCat. No.: HY-118084CAS No.: 368836-72-0Synonyms: Tyrene CR-4LS-104 (Tyrene CR-4) is a non-ATP-competitive kinase inhibitor against JAK2, Bcr-Abl and FLT3. LS-104 potently induces apoptosis in JAK2V617F-positive cells and inhibits JAK2 autophosphorylation and downstream signal transduction. LS-104 also inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells. LS-104 is a hydroxystyryl-acrylonitrile compound, which is promising for research of myeloproliferative disorders and refractory/relapsed hematologic malignancies.
-
FLT3-IN-20
0 ImagesCat. No.: HY-155770FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor with IC50 values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-20 has anti-proliferation efficacy in FLT3-ITD-positive AML cell lines MV4-11 and MOLM-13 (7 and 9 nM, respectively) and the MOLM-13 variant (4 nM) with the FLT3-ITD-D835Y mutation. FLT3-IN-20 can be used in research of cancer.
-
Multi-kinase-IN-12
0 ImagesCat. No.: HY-18692CAS No.: 597544-21-3Multi-kinase-IN-12 is a non-selective multi-target inhibitor, with IC50 values against human targets as follows: Flt3 < 0.001 μM, c-Src 0.002 μM, KDR 0.004 μM, Eph-A2, MNK-1 and Flt1 0.011 μM, Lck 0.016 μM, Rsk1 0.21 μM, and α2 subunit of AMPK 0.041 μM. Multi-kinase-IN-12 can be used in research related to solid tumors.
-
TTT 3002
0 ImagesCat. No.: HY-111249CAS No.: 871037-95-5TTT 3002 is a potent and orally active FLT3 inhibitor. TTT 3002 potently inhibits FLT3 phosphorylation by activating mutations at residue D835, with an IC50 of 0.2 nM. TTT 3002 can be used for AML (acute myeloid leukemia) research.
-
FLC-8
0 ImagesCat. No.: HY-182937CAS No.: 3100242-36-9FLC-8 is an orally active FLT3 inhibitor with IC50 values of 10.2 nM, 11.6 nM and 24.10 nM against human FLT3-WT, FLT3-G697R and FLT3-N676D, respectively. FLC-8 inhibits FLT3 autophosphorylation and downstream STAT5, AKT and ERK signaling pathways, and induces apoptosis in acute myeloid leukemia (AML) cells. FLC-8 exhibits potent antitumor activity in the MV4-11 xenograft model. FLC-8 can be used for the research of acute myeloid leukemia.
-
HP1142
0 ImagesCat. No.: HY-145691CAS No.: 381173-58-6HP1142 is a potent and selective inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutation). HP1142 is a benzoimidazole scaffold-based compound. HP1142 has the potential for the research of FLT3/ITD leukemia.
